SPRY: Disruptor Positioning And Recent Approvals Will Support Future Upside Potential

Analysts have adjusted their price target for ARS Pharmaceuticals slightly from about $27.00 to roughly $26.71. This reflects updated assumptions around discount rates, profit margins, revenue growth, and future P/E expectations following recent bullish Street research initiations.

Analyst Commentary

Recent research initiations frame ARS Pharmaceuticals as a potential disruptor, with analysts updating their models to reflect revised discount rates, margin assumptions, and P/E expectations. That work sits behind the modest shift in price target and gives a clearer view of where the Street sees execution risk and opportunity.

Bullish Takeaways

Bullish analysts view the disruptor positioning as a key support for long term growth assumptions, which feeds into their willingness to underwrite higher revenue trajectories in valuation models.
The constructive stance often assumes the company can scale operations efficiently, which underpins more optimistic profit margin paths and supports the current P/E framework used in price targets.
Supportive research typically treats current funding and commercial plans as sufficient for the next phase of execution, which reduces perceived discount rate risk in their models.
These analysts see room for multiple expansion over time if management delivers on product rollout milestones, so they keep some flexibility in future P/E expectations.

Bearish Takeaways

More cautious analysts focus on execution risk around scaling a disruptor business model, which can constrain assumed revenue growth in their scenarios.
There is concern that profit margins could come under pressure if commercialization or manufacturing costs run higher than planned, which would weigh on earnings and compress P/E assumptions.
Some bearish analysts flag uncertainty around how quickly the company can convert its positioning into consistent cash flows, which supports a higher discount rate in their valuation work.
Cautious views also point to the possibility that investor enthusiasm may already be reflected in current valuation levels, leaving less room for upside if execution is slower than expected.

What's in the News

Health Canada approved neffy 2 mg epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis, in adults and children who weigh 30 kg or more, with commercial availability in Canada expected in summer 2026 through ALK Abelló, which holds exclusive commercialization rights in Europe, Canada, the U.K. and select other regions (Key Developments).
Under the ALK licensing agreement, ARS Pharmaceuticals has received US$155 million in upfront and milestone payments and is eligible for up to an additional US$310 million in regulatory and sales milestones, plus tiered, double digit royalties in the teens on net sales in licensed territories, while ARS remains responsible for manufacturing and supply (Key Developments).
The U.S. FDA approved an update to the neffy 1 mg prescribing information to remove age restrictions so that all children and adults who weigh at least 33 lbs can use the product, alongside packaging and storage changes such as including a free carrying case and more flexible guidance around sniffing, temperature excursions and freezing (Key Developments).
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending expansion of the EURneffy marketing authorization to include a 1 mg nasal adrenaline spray for children who weigh 15 kg to less than 30 kg, extending the previously granted approval for the 2 mg dose in adults and children who weigh at least 30 kg (Key Developments).
Multiple scientific and health economic presentations on neffy, including poster sessions, a healthcare professional case report and late breaking data from ALK, are scheduled for the 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting, focusing on areas such as patient preference, usability and pharmacokinetic comparisons versus injectable epinephrine (Key Developments).

Valuation Changes

Fair Value: Target fair value has edged down slightly from $27.00 to about $26.71 per share.
Discount Rate: The assumed discount rate has risen slightly from 7.40% to about 7.52%, pointing to a modestly higher required return in the model.
Revenue Growth: Modeled revenue growth is broadly unchanged, moving marginally from about 71.86% to roughly 71.91%.
Net Profit Margin: The assumed net profit margin has risen slightly from about 5.70% to roughly 5.94%, reflecting a small adjustment to long term profitability expectations.
Future P/E: The future P/E multiple has been trimmed from about 140x to roughly 133x, indicating a somewhat more conservative valuation multiple being applied.

28 views

Key Takeaways

Accelerating demand and expanded access for neffy, especially in pediatric and school settings, is driving significant revenue and earnings growth opportunities.
Global expansion, new clinical indications, and strong market penetration strategies are broadening revenue streams and creating multiple long-term growth drivers.
Dependence on a single product, high marketing spend, pricing pressures, and rising competition create substantial risks to sustainable growth and profitability.

Catalysts

About ARS Pharmaceuticals

A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.What are the underlying business or industry changes driving this perspective?

Increasing global prevalence of severe allergies and anaphylaxis, alongside rising awareness of rapid allergic reaction treatment, is expanding the long-term demand for needle-free emergency therapies like neffy-which is reflected in accelerating prescription growth and should drive sustained top-line revenue expansion.
Growing pediatric and school-based adoption-supported by program engagement, recent pediatric dosing approvals, and legislative updates in multiple states-positions neffy to capture untapped patient pools, increasing revenue scale and supporting durable earnings growth as the addressable market broadens.
Successful global rollout initiatives, with neffy launches in Germany and the UK and pending regulatory approvals in Canada, Australia, Japan, and China, create a catalyst for international revenue growth and milestone payments, diversifying and expanding overall revenue streams.
Rapid removal of access barriers (93% payer coverage, reduced prior authorization requirements, high co-pay support adoption) combined with a robust DTC campaign is improving market penetration, which is likely to drive further revenue growth and enhance net margins via operating leverage as sales increase.
Expansion of intranasal epinephrine indications (e.g., ongoing Phase IIb clinical trial in chronic spontaneous urticaria) could unlock high-value new use cases for neffy, creating future growth drivers for both top-line revenue and long-term earnings.

ARS Pharmaceuticals Earnings and Revenue Growth

ARS Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ARS Pharmaceuticals's revenue will grow by 71.9% annually over the next 3 years.
Analysts assume that profit margins will increase from -203.3% today to 5.9% in 3 years time.
Analysts expect earnings to reach $25.4 million (and earnings per share of $0.22) by about May 2029, up from -$171.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $111.2 million in earnings, and the most bearish expecting $-108.6 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 134.0x on those 2029 earnings, up from -4.8x today. This future PE is greater than the current PE for the US Biotechs industry at 16.3x.
Analysts expect the number of shares outstanding to grow by 1.1% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.52%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Heavy reliance on neffy as a single lead asset exposes ARS to significant product concentration risk; any future regulatory setbacks, commercial issues, or competitive pressures directly threaten topline revenue and earnings due to lack of diversification.
Intense investment in DTC marketing and high SG&A expenses, without assurance of sustained DTC effectiveness or ultimate script conversion, could pressure near
and mid-term net margins and increase risk of poor operating leverage if prescription growth plateaus.
Industry-wide drug price transparency, reimbursement pressures, and increased gross-to-net (GTN) deductions are already compressing ARS's net product revenue; ongoing payer negotiations and co-pay support could further erode long-term profitability.
Advancing competition in non-injectable epinephrine or alternative anaphylaxis treatments, or disruptive next-generation delivery methods from larger or more resourceful pharma, could quickly diminish neffy's commercial opportunity, affecting future revenue growth.
Global expansion is dependent on partnership milestones, successful international regulatory approvals, and country-specific market adoption, all of which encounter substantial execution risk and could delay or cap multi-year revenue and earnings scalability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $26.71 for ARS Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $34.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $428.2 million, earnings will come to $25.4 million, and it would be trading on a PE ratio of 134.0x, assuming you use a discount rate of 7.5%.
Given the current share price of $8.26, the analyst price target of $26.71 is 69.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ARS Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Worldwide Allergy Trends Will Expand Needle-Free Treatment Access